You are here: HomeSolutionsIndustriesConsumer Health
print my pages

Country Report

Consumer Health in New Zealand

May 2011

Price: $2,400

About this Report

About this Report

Delivery method: instant download
Report format: PDF doc_pdf.png (download a sample)
Market statistics: Excel workbook doc_excel_table.png (download a sample)

Overview

Discover the latest market trends and uncover sources of future market growth for the Consumer Health industry in New Zealand with research from Euromonitor's team of in-country analysts.

Find hidden opportunities in the most current research data available, understand competitive threats with our detailed market analysis, and plan your corporate strategy with our expert qualitative analysis and growth projections.

If you're in the Consumer Health industry in New Zealand, our research will save you time and money while empowering you to make informed, profitable decisions.

When you purchase this report, you also get the data and the content from these category reports in New Zealand for free:

The Consumer Health in New Zealand market research report includes:

  • Analysis of key supply-side and demand trends
  • Detailed segmentation of international and local products
  • Historic volumes and values, company and brand market shares
  • Five year forecasts of market trends and market growth  
  • Robust and transparent market research methodology, conducted in-country

Our market research reports answer questions such as:

  • What is the market size of Consumer Health in New Zealand?
  • What are the major brands in New Zealand?
  • What are the main trends in OTC Healthcare?

Why buy this report?

  • Gain competitive intelligence about market leaders
  • Track key industry trends, opportunities and threats
  • Inform your marketing, brand, strategy and market development, sales and supply functions

This industry report originates from Passport, our Consumer Health market research database.

Sample Analysis

EXECUTIVE SUMMARY

Consumer health remains strong during economic downturn

Consumer health in New Zealand saw retail value growth of 4% in 2010, slightly down on the review period CAGR. While many categories in New Zealand faced declining sales in 2009 and 2010, consumer health as a whole maintained strong growth. Consumers still value their health during periods of economic downturn.

Changes in consumer buying behaviour

While consumer health continued to perform well in 2010, consumers demonstrated greater price consciousness. This resulted in an increase in sales of generics and private label products in numerous product categories

Vitaco Health Ltd maintains number one position

Vitaco Health Ltd remained the leading player in New Zealand’s consumer health market in 2010. The company’s wide range of trusted brands and extensive distribution network contribute to its unparalleled success.

Internet retailing sees significant growth

Internet retailing continued to show growth in 2010, and this is expected to continue over the forecast period. Many online consumer health retailers existed in 2010, offering wide product ranges at generally competitive prices. Chemists/pharmacies, other healthcare specialist retailers and grocery retailers all remain very important to consumer health. Consumers generally view grocery channels as the most economical in which to make such purchases. Direct selling channels also maintained important positions in 2010, with USANA Health Science (NZ) Corp and Amway of New Zealand Ltd holding second and third positions within consumer health in New Zealand in 2010.

Forecast period growth expected

A forecast period retail value CAGR of 2% is expected for consumer health in New Zealand. Various factors are expected to contribute to this growth; however the trends relating to self-care, self-medication and prevention are expected to play significant roles.

Table of Contents

Table of Contents

Consumer Health in New Zealand - Industry Overview

EXECUTIVE SUMMARY

Consumer health remains strong during economic downturn

Changes in consumer buying behaviour

Vitaco Health Ltd maintains number one position

Internet retailing sees significant growth

Forecast period growth expected

KEY TRENDS AND DEVELOPMENTS

Christchurch earthquake implications

  • Table 1 Economic Projections 2011

Tobacco smoking declines

Natural healing and prevention

Private label and generics

Self-medication on the Increase

Competition intensifies among manufacturers and retailers

MARKET INDICATORS

  • Table 2 Consumer Expenditure on Health Goods and Medical Services 2005-2010
  • Table 3 Life Expectancy at Birth 2005-2010

MARKET DATA

  • Table 4 Sales of Consumer Health by Category: Value 2005-2010
  • Table 5 Sales of Consumer Health by Category: % Value Growth 2005-2010
  • Table 6 Consumer Health Company Shares by Value 2006-2010
  • Table 7 Consumer Health Brand Shares by Value 2007-2010
  • Table 8 Penetration of Private Label by Category 2005-2010
  • Table 9 Sales of Consumer Health by Distribution Format: % Analysis 2005-2010
  • Table 10 Sales of Consumer Health by Category and Distribution Format: % Analysis 2010
  • Table 11 Forecast Sales of Consumer Health by Category: Value 2010-2015
  • Table 12 Forecast Sales of Consumer Health by Category: % Value Growth 2010-2015

APPENDIX

OTC registration and classification

Vitamins and dietary supplements’ registration and classification

Self-medication/self-care and preventative medicine

Switches

  • Summary 1 OTC Healthcare Switches 2008-2010

DEFINITIONS

  • Summary 2 Research Sources

Consumer Health in New Zealand - Company Profiles

Douglas Pharmaceuticals Ltd in Consumer Health (New Zealand)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 4 Douglas Pharmaceuticals Ltd: Competitive Position 2010

Go Healthy New Zealand Ltd in Consumer Health (New Zealand)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 6 Go Healthy New Zealand Ltd: Competitive Position 2010

Mylan New Zealand Ltd in Consumer Health (New Zealand)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 8 Mylan New Zealand Ltd: Competitive Position 2010

Red Seal Natural Health Ltd in Consumer Health (New Zealand)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

  • Summary 10 Red Seal Natural Health Ltd: Production Statistics 2010

COMPETITIVE POSITIONING

  • Summary 11 Red Seal Natural Health Ltd: Competitive Position 2010

Vitaco Health Ltd in Consumer Health (New Zealand)

STRATEGIC DIRECTION

KEY FACTS

COMPANY BACKGROUND

PRODUCTION

COMPETITIVE POSITIONING

  • Summary 13 Vitaco Health Ltd: Competitive Position 2010

Adult Mouth Care in New Zealand - Category Analysis

HEADLINES

TRENDS

  • 2010’s retail value growth of 2% was slightly below the review period CAGR of 3%. Adult mouth care is a mature category in New Zealand and does not exhibit unique growth drivers. The economic downturn resulted in consumers becoming more price-conscious, with greater importance placed on bargain products and discounts. Consumers learnt to wait and make purchases when promotions or discounting occurred.

SWITCHES

COMPETITIVE LANDSCAPE

  • Reckitt Benckiser New Zealand Ltd held the greatest retail sales share in 2010 at 35% for the Bonjela Oral Gel brand. Hamilton Pharmaceutical Pty Ltd’s Orased Gel brand was placed second with a 26% share. Third place was awarded to iNova Pharmaceuticals (Australia) Pty Ltd’s Difflam Mouth Gel with 16%.

PROSPECTS

  • Adult mouth care in New Zealand is expected to see a constant value CAGR of 0.5% over the forecast period. Increased price competition is expected to limit value growth potential, and the lack of significant growth drivers is expected to continue in coming years.

CATEGORY DATA

  • Table 13 Sales of Adult Mouth Care: Value 2005-2010
  • Table 14 Sales of Adult Mouth Care: % Value Growth 2005-2010
  • Table 15 Adult Mouth Care Company Shares by Value 2006-2010
  • Table 16 Adult Mouth Care Brand Shares by Value 2007-2010
  • Table 17 Forecast Sales of Adult Mouth Care: Value 2010-2015
  • Table 18 Forecast Sales of Adult Mouth Care: % Value Growth 2010-2015

Analgesics in New Zealand - Category Analysis

HEADLINES

TRENDS

  • In 2010 analgesics saw retail value growth of 1% – short of the review period CAGR of 2%. This is partly due the decreasing sales of the largest niche, acetaminophen, which accounts for 40% of analgesics’ total value. Furthermore, the aspirin niche is mature and stagnant.

SWITCHES

COMPETITIVE LANDSCAPE

  • GlaxoSmithKline New Zealand Ltd led sales in 2010 with a retail value share of 43%, through sales worth NZ$19 million. Reckitt Benckiser New Zealand Ltd was in second place with a share of 32%, and a total of NZ$14 million. These two companies dominate analgesics due to their high levels of innovation, research and development, high brand awareness and large marketing, promotion and advertising budgets. Competition is intense between these two companies, and the gap between them in terms of OTC analgesics in New Zealand decreased in 2010. GlaxoSmithKline New Zealand Ltd saw a slight decline in value share, whereas Reckitt Benckiser New Zealand Ltd saw an increase of just over one percentage point – the largest increase within the category.

PROSPECTS

  • Innovation will represent a key growth driver over the forecast period. Combination analgesics are expected to perform better than other niches due to innovation and anticipated new product launches. Ibuprofen is also forecast to perform well due to decreasing acetaminophen sales.

CATEGORY DATA

  • Table 19 Sales of Analgesics by Category: Value 2005-2010
  • Table 20 Sales of Analgesics by Category: % Value Growth 2005-2010
  • Table 21 Topical Analgesics/Anaesthetic by Format: % Value Breakdown 2005-2010
  • Table 22 Analgesics Company Shares by Value 2006-2010
  • Table 23 Analgesics Brand Shares by Value 2007-2010
  • Table 24 Forecast Sales of Analgesics by Category: Value 2010-2015
  • Table 25 Forecast Sales of Analgesics by Category: % Value Growth 2010-2015

Calming and Sleeping in New Zealand - Category Analysis

HEADLINES

TRENDS

  • 2010’s increased of 7% was higher than the 6% review period CAGR. Calming and sleeping products represented one of the most dynamic consumer health categories in 2010, demonstrating that the amount of people who are aware of the importance of adequate rest and a good night’s sleep has increased. It also indicates that the amount of people who lead busy and stressful lifestyles in New Zealand, which cause sleep disorders, has increased.

SWITCHES

COMPETITIVE LANDSCAPE

  • Vitaco Health Ltd was the leading player in calming and sleeping products in 2010, with a retail value share of 43% – a slight increase on 2009. Vitaco Health Ltd’s strong performance is attributable to its wide range of domestic brands, such as Be Sleepy, and Healtheries Easy Sleep capsules, which contain valerian, passion flower, skullcap, hops and wild lettuce, being preferred by consumers over international brands. Furthermore, the Healtheries range is available in supermarkets at competitive prices.

PROSPECTS

  • The continuation of the health and wellness trend will continue to contribute to the performance of the calming and sleeping products environment in coming years, as consumers learn more about the importance of healthier lifestyles.

CATEGORY DATA

  • Table 26 Sales of Calming and Sleeping: Value 2005-2010
  • Table 27 Sales of Calming and Sleeping: % Value Growth 2005-2010
  • Table 28 Calming and Sleeping Company Shares by Value 2006-2010
  • Table 29 Calming and Sleeping Brand Shares by Value 2007-2010
  • Table 30 Forecast Sales of Calming and Sleeping: Value 2010-2015
  • Table 31 Forecast Sales of Calming and Sleeping: % Value Growth 2010-2015

Cough, Cold and Allergy (Hay Fever) Remedies in New Zealand - Category Analysis

HEADLINES

TRENDS

  • The classification of pseudoephedrine containing medicines was under review and received a lot of media attention in 2009 and 2010. Ephedrine and pseudoephedrine are active ingredients used in the manufacture of the class A controlled drug methamphetamine. Pseudoephedrine is currently available over the counter in cold and flu remedies from pharmacies. The reclassifications will make both ephedrine and pseudoephedrine prescription-only. The review is in accordance with the October 2009 announcement by Prime Minister John Key regarding the government’s action plan to decrease the negative effects in New Zealand of the highly addictive and harmful drug, known as P. During June 2009 the Expert Advisory Committee on Drugs determined that legislative change was required on the grounds that effective alternative remedies to ephedrine and pseudoephedrine are available, and that the risk of pseudoephedrine being diverted into the manufacture of methamphetamine outweighs the requirement for its on-going over-the-counter availability. Therefore, the purpose of the reclassifications is to restrict the availability of these substances and make it difficult for potential manufacturers of methamphetamine to access the key ingredients required to make the drug. Demand and supply of pseudoephedrine-containing medicines both reduced further in 2010.

SWITCHES

COMPETITIVE LANDSCAPE

  • Reckitt Benckiser New Zealand Ltd continued to dominate the category in 2010, with a retail value share of 28%, up half a percentage point from 2009. The company’s Lemsip, Strepsils and Nurofen brands continue to perform well, keeping up with consumer trends through innovation and marketing. These are underpinned by high levels of advertising and promotion, which bolster high brand awareness among consumers. The Lemsip brand held the highest brand share in 2010, with 15% of sales.

PROSPECTS

  • From 1 May 2011, cough and cold medicines for children under 12 years of age which contain dextromethorphan and phenylephrine will become pharmacy-only products. Products containing these ingredients may only be sold outside pharmacies from 1 May 2011, if they are re-labelled for use in adults and children over 12 years of age. The Pharmacy Guild believes that reclassification will significantly increase the safety and effectiveness of treatment for patients suffering coughs and colds. However, the New Zealand Self-Medication Industry Association believes that it will reduce access and availability for consumers to these products and will increase costs for suppliers and thus consumers.

CATEGORY DATA

  • Table 32 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2005-2010
  • Table 33 Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2005-2010
  • Table 34 Sales of Decongestants by Category: Value 2005-2010
  • Table 35 Sales of Decongestants by Category: % Value Growth 2005-2010
  • Table 36 Sales of Child-specific Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2005-2010
  • Table 37 Sales of Child-specific Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2005-2010
  • Table 38 Cough, Cold and Allergy (Hay Fever) Remedies Company Shares by Value 2006-2010
  • Table 39 Cough, Cold and Allergy (Hay Fever) Remedies Brand Shares by Value 2007-2010
  • Table 40 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: Value 2010-2015
  • Table 41 Forecast Sales of Cough, Cold and Allergy (Hay Fever) Remedies by Category: % Value Growth 2010-2015

Digestive Remedies in New Zealand - Category Analysis

HEADLINES

TRENDS

  • As in 2009, consumers trended towards lower-priced products in 2010, affecting retail value growth. This price-conscious trend in 2010, and the fact that products are mature within the category, both contributed to 2010’s growth rate of 1% being lower than the review period CAGR of just over 2%.

SWITCHES

COMPETITIVE LANDSCAPE

  • Johnson & Johnson Pacific (NZ) Ltd was the category leader in 2010 with a 24% value share. The company’s Mylanta brand contributes strongly to the company’s leading position. However, Mylanta’s share is relatively stagnant.

PROSPECTS

  • The -1% constant value CAGR predicted for the forecast period is slightly weaker than the review period performance. The category is mature and promotional activities are expected to remain low.

CATEGORY DATA

  • Table 42 Sales of Digestive Remedies by Category: Value 2005-2010
  • Table 43 Sales of Digestive Remedies by Category: % Value Growth 2005-2010
  • Table 44 Digestive Remedies Company Shares by Value 2006-2010
  • Table 45 Digestive Remedies Brand Shares by Value 2007-2010
  • Table 46 Forecast Sales of Digestive Remedies by Category: Value 2010-2015
  • Table 47 Forecast Sales of Digestive Remedies by Category: % Value Growth 2010-2015

Ear Care in New Zealand - Category Analysis

HEADLINES

TRENDS

  • 2010 saw a current value CAGR of 4%, which was slightly higher than 2009’s growth of 3%. Ear care in New Zealand was stagnating in 2010, with no special or unique growth drivers.

SWITCHES

COMPETITIVE LANDSCAPE

  • Norgine Ltd led sales in 2010 with its Waxsol brand. It achieved a retail value share of 30%. While the company’s share saw minimal movement over the review period, it has continued to maintain the number one position.

PROSPECTS

  • The forecast period retail constant value CAGR of -0.3% is significantly lower than review period growth. Retail sales are expected to decrease to just over NZ$2 million by 2015.

CATEGORY DATA

  • Table 48 Sales of Ear Care: Value 2005-2010
  • Table 49 Sales of Ear Care: % Value Growth 2005-2010
  • Table 50 Ear Care Company Shares by Value 2006-2010
  • Table 51 Ear Care Brand Shares by Value 2007-2010
  • Table 52 Forecast Sales of Ear Care: Value 2010-2015
  • Table 53 Forecast Sales of Ear Care: % Value Growth 2010-2015

Emergency Contraception in New Zealand - Category Analysis

HEADLINES

TRENDS

  • The 2010 growth rate of 4% was lower than the review period CAGR of 5% as consumers became more aware of the importance of preventative contraceptive methods.

COMPETITIVE LANDSCAPE

  • Levonelle by Schering (NZ) Ltd remained the only OTC emergency contraception products available in New Zealand in 2010. Schering (NZ) Ltd is part of Bayer AG. Levonelle therefore continues to have 100% share.

PROSPECTS

  • The forecast period CAGR of 2% is below the review period constant value CAGR. Prescription emergency contraception and related subsidies, new contraceptive methods and increased consumer education with regard to preventative contraception are all potential forecast threats to OTC emergency contraception.

CATEGORY DATA

  • Table 54 Sales of Emergency Contraception: Value 2005-2010
  • Table 55 Sales of Emergency Contraception: % Value Growth 2005-2010
  • Table 56 Emergency Contraception Company Shares by Value 2006-2010
  • Table 57 Emergency Contraception Brand Shares by Value 2007-2010
  • Table 58 Forecast Sales of Emergency Contraception: Value 2010-2015
  • Table 59 Forecast Sales of Emergency Contraception: % Value Growth 2010-2015

Eye Care in New Zealand - Category Analysis

HEADLINES

TRENDS

  • The 2010 4% growth rate was slightly lower than the review period CAGR of 5%. This is attributable to the fact that standard eye care is relatively mature and shows fierce competition, along with a high level of product choice. Allergy eye care, on the other hand, is not so mature, and outperformed the only other category, standard eye care.

SWITCHES

COMPETITIVE LANDSCAPE

  • Allergan New Zealand Ltd, Alcon NZ Ltd and Prestige Brands International Inc held a combined eye care retail value share of 76%, each holding value shares of 25-26%.

PROSPECTS

  • The 2% proposed forecast period retail value CAGR for the category is slightly down on the review period CAGR. The dominant niche, standard eye care, is relatively mature. Furthermore, competition within standard eye care is expected to remain strong, and the competition within allergy eye care is expected to intensify. Strong competition will increase price competition, which will result in lower forecast period growth. The maturity levels of the two niches will result in allergy eye care outperforming standard eye care over the forecast period, with forecast CAGRs of 3% and 1% respectively.

CATEGORY DATA

  • Table 60 Sales of Eye Care by Category: Value 2005-2010
  • Table 61 Sales of Eye Care by Category: % Value Growth 2005-2010
  • Table 62 Standard Eye Care by Type: % Value Breakdown 2007-2010
  • Table 63 Eye Care Company Shares by Value 2006-2010
  • Table 64 Eye Care Brand Shares by Value 2007-2010
  • Table 65 Forecast Sales of Eye Care by Category: Value 2010-2015
  • Table 66 Forecast Sales of Eye Care by Category: % Value Growth 2010-2015

Herbal/Traditional Products in New Zealand - Category Analysis

HEADLINES

TRENDS

  • The proposed regulatory scheme for the New Zealand natural health products industry is in the early stage of being developed. Regulation will include registration and licensing of vitamins and dietary supplements and herbal/traditional products. The industry is in need of regulation in order to protect consumers from unsafe and low quality products, and it is proposed that regulation will improve the general quality of natural and herbal remedies, etc..

COMPETITIVE LANDSCAPE

  • Vitaco Health Ltd was the leading player in the category in 2010, with a retail value share of 12%. However, the company’s share within the category has been in decline, down from 14% in 2007 and 12% in 2009. The cause of this is the decline of the Healtheries brand within the category.

PROSPECTS

  • The forecast period CAGR of 1% is expected to lead to a value total of NZ$73 million in 2015. This forecast period growth rate is an improvement on the review period constant value CAGR of -2%.

CATEGORY DATA

  • Table 67 Sales of Herbal/Traditional Products: Value 2005-2010
  • Table 68 Sales of Herbal/Traditional Products: % Value Growth 2005-2010
  • Table 69 Herbal/Traditional Products Company Shares 2006-2010
  • Table 70 Herbal/Traditional Products Brand Shares 2007-2010
  • Table 71 Forecast Sales of Herbal/Traditional Products: Value 2010-2015
  • Table 72 Forecast Sales of Herbal/Traditional Products: % Value Growth 2010-2015

Medicated Skin Care in New Zealand - Category Analysis

HEADLINES

TRENDS

  • The recessionary economic environment and high unemployment rates in New Zealand continued to increase consumer price-awareness in 2010, and medicated skin care retail sales slowed down in 2009 and 2010 as a result. Furthermore, the category is mature and competition is fierce. These factors are reflected in the 2010 retail value growth rate of 2% being below the review period CAGR of 4%.

SWITCHES

COMPETITIVE LANDSCAPE

  • Johnson & Johnson Pacific (NZ) Ltd remained the medicated skin care leader in New Zealand in 2010. The company held a retail value share of 23%. Its brands Regaine, Nizoral and Neutrogena performed well and have high brand awareness due to high levels of review period promotional support. The company’s Daktarin brand also performed well in 2010, leading the antifungals niche.

PROSPECTS

  • The forecast period is predicted to see a constant value CAGR of 0.5%. Stagnating forecast period sales are expected due to the strong competition that is expected to continue from prescription-only, cosmeceutical and natural skin care products. Also, child-specific medicated skin care products are expected to decline throughout the forecast period due to the ageing population.

CATEGORY DATA

  • Table 73 Sales of Medicated Skin Care by Category: Value 2005-2010
  • Table 74 Sales of Medicated Skin Care by Category: % Value Growth 2005-2010
  • Table 75 Acne Treatments by Format: % Value Breakdown 2005-2010
  • Table 76 Medicated Skin Care Company Shares by Value 2006-2010
  • Table 77 Medicated Skin Care Brand Shares by Value 2007-2010
  • Table 78 Acne Treatments Brand Shares by Value 2007-2010
  • Table 79 Hair Loss Treatments Brand Shares by Value 2007-2010
  • Table 80 Forecast Sales of Medicated Skin Care by Category: Value 2010-2015
  • Table 81 Forecast Sales of Medicated Skin Care by Category: % Value Growth 2010-2015

NRT Smoking Cessation Aids in New Zealand - Category Analysis

HEADLINES

TRENDS

  • The 2010 current value terms growth of 7% for NRT smoking cessation aids was on par with the review period CAGR. This was due to numerous initiatives throughout the review period, continuing into 2010.

SWITCHES

COMPETITIVE LANDSCAPE

  • Johnson & Johnson Pacific (NZ) Ltd was the leading company within the category in 2010, showing its strength through a retail value share of 72%, with the popular Nicorette brand. Novartis New Zealand Ltd maintained second position with a share of 27%, incorporating the Habitrol and Nicotinell brands. The Activestop programme by Nicorette continued to become popular among consumers in 2010.

PROSPECTS

  • Smoking is not looked upon fondly in New Zealand, and this trend is expected to intensify over the forecast period. The population of New Zealand is expected to increase, although the total number of smokers is expected to decline from 713,270 in 2010 to 698,630 in 2015. Female smoking rates are anticipated to decline at a faster rate than males.

CATEGORY INDICATORS

  • Table 82 Number of Smokers by Gender 2005-2010

CATEGORY DATA

  • Table 83 Sales of NRT Smoking Cessation Aids by Category: Value 2005-2010
  • Table 84 Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2005-2010
  • Table 85 NRT Gum Flavours: % Value Breakdown 2006-2010
  • Table 86 NRT Smoking Cessation Aids Company Shares by Value 2006-2010
  • Table 87 NRT Smoking Cessation Aids Brand Shares by Value 2007-2010
  • Table 88 Forecast Sales of NRT Smoking Cessation Aids by Category: Value 2010-2015
  • Table 89 Forecast Sales of NRT Smoking Cessation Aids by Category: % Value Growth 2010-2015

OTC Triptans in New Zealand - Category Analysis

HEADLINES

TRENDS

  • OTC triptans were first available in New Zealand in 2007, after being approved by Medsafe in 2006. The category saw rapid growth of 110% in 2008, a significantly reduced 20% increase in 2009, and a 15% rise in 2010. As the majority of triptans in New Zealand are prescription-only, migraine sufferers are generally unaware that these products are available on an OTC basis.

SWITCHES

COMPETITIVE LANDSCAPE

  • Arrow Pharmaceuticals Pty Ltd’s Mygran brand was discontinued in 2009, leaving Sumagran Active from Mylan New Zealand Ltd with an OTC triptans monopoly in 2010, and therefore a 100% share. Mylan New Zealand Ltd is part of Mylan Inc.

PROSPECTS

  • An international scientific team has identified for the first time a genetic risk factor associated with common migraines. It is claimed that their research could open the path for new treatments to prevent migraine attacks.

CATEGORY DATA

  • Table 90 Sales of OTC Triptans: Value 2007-2010
  • Table 91 Sales of OTC Triptans: % Value Growth 2007-2010
  • Table 92 OTC Triptans Company Shares by Value 2006-2010
  • Table 93 OTC Triptans Brand Shares by Value 2007-2010
  • Table 94 Forecast Sales of OTC Triptans: Value 2010-2015
  • Table 95 Forecast Sales of OTC Triptans: % Value Growth 2010-2015

Sports Nutrition in New Zealand - Category Analysis

HEADLINES

TRENDS

  • Sports nutrition sales were negatively affected in both 2009 and 2010 by the recessionary economic environment. This is evident in 2010’s growth of 1%, being lower than the review period CAGR of 4%.

COMPETITIVE LANDSCAPE

  • Vitaco Health Ltd held a 45% value share in sports nutrition in 2010, as a result of its well-known Balance brand. It has a strong presence in gyms, sports nutrition stores, chemists/pharmacies, sports goods stores and other healthcare specialist retailers. Balance sponsors numerous athletes, for example the 8-times New Zealand Ironman Champion Cameron Brown, and triathlon champion Nicky Samuels.

PROSPECTS

  • The -0.5% forecast period CAGR is expected for sports nutrition in New Zealand, and it is forecast to remain one of the smallest consumer health categories, with total retail value sales worth less than NZ$17 million in 2015.

CATEGORY DATA

  • Table 96 Sports Nutrition, Category Rankings 2010
  • Table 97 Sales of Sports Nutrition: Value 2005-2010
  • Table 98 Sales of Sports Nutrition: % Value Growth 2005-2010
  • Table 99 Sports Nutrition By Format: % Value Breakdown 2007-2010
  • Table 100 Sports Nutrition Company Shares 2006-2010
  • Table 101 Sports Nutrition Brand Shares 2007-2010
  • Table 102 Forecast Sales of Sports Nutrition: Value 2010-2015
  • Table 103 Forecast Sales of Sports Nutrition: % Value Growth 2010-2015

Vitamins and Dietary Supplements in New Zealand - Category Analysis

HEADLINES

TRENDS

  • The 5% 2010 retail value growth of vitamins and dietary supplements in 2010 exceeded the review period CAGR of 4%.

VITAMINS

DIETARY SUPPLEMENTS

COMPETITIVE LANDSCAPE

  • Vitaco Health Ltd lead the vitamins and dietary supplements category in 2010, with a retail value share of 22%, up from 21% in 2009. Vitaco Health Ltd has maintained the leading position since its inception in 2007, and its share slightly increased during each of those four years. The Healtheries brand continues to perform well, as it is a well-established and trusted brand among New Zealand consumers.

PROSPECTS

  • Vitamins and dietary supplements is expected to perform well over the forecast period. The forecast period CAGR is expected to stand at 3% to reach NZ$247 million in 2015.

CATEGORY DATA

  • Table 104 Sales of Vitamins and Dietary Supplements by Category: Value 2005-2010
  • Table 105 Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2005-2010
  • Table 106 Dietary Supplements by Positioning 2005-2010
  • Table 107 Vitamins and Dietary Supplements Company Shares by Value 2006-2010
  • Table 108 Vitamins and Dietary Supplements Brand Shares by Value 2007-2010
  • Table 109 Vitamins Brand Shares by Value 2007-2010
  • Table 110 Dietary Supplements Brand Shares by Value 2007-2010
  • Table 111 Forecast Sales of Vitamins and Dietary Supplements by Category: Value 2010-2015
  • Table 112 Forecast Sales of Vitamins and Dietary Supplements by Category: % Value Growth 2010-2015

Weight Management in New Zealand - Category Analysis

HEADLINES

TRENDS

  • Obesity rates in New Zealand have been increasing since the 1990s. A 2-year study conducted by Statistics New Zealand found that one in seven New Zealanders – 13% – have healthy lifestyles. Obesity, which is a major risk factor for many chronic diseases, is more prevalent among Maori, Pacific and South Asian communities within New Zealand. The Ministry of Health (MoH) is focused on reducing rates of obesity. Released on 30 September 2010, the MoH implementation plan for clinical guidelines which frontline health care workers can use when helping patients achieve and maintain a healthy weight includes the following: raise awareness, identify need and the context for action, determine options for action (Food, Activity and Behaviour (FAB) strategies), and maintain contact and support. The Ministry of Health “Weight Management” website strongly focuses on weight management and lifestyle advice. Healthy Eating – Healthy Action (HEHA) is the Ministry of Health’s strategic approach to improving nutrition, increasing physical activity and achieving healthy weight for all New Zealanders. SPARC (Sport and Recreation New Zealand) is an important partner in HEHA. Improving nutrition, increasing physical activity, and reducing obesity are three of the 13 health priorities identified in the New Zealand Health Strategy.

COMPETITIVE LANDSCAPE

  • Vitaco Health Ltd was the leading player in weight management in New Zealand in 2010. The company has a retail value share of 28%, and its Nutra-life and Healtheries Natural Slim brands are placed first and second with value shares of around 14% each. Vitaco Health Ltd holds the leadership role due to the extensive distribution throughout New Zealand in pharmacy and grocery channels of its well established and trusted brands. Herbalife (NZ) Ltd was placed with a 13% value share, and Etika (NZ) Ltd third with 13%.

PROSPECTS

  • Consumer health weight management products are expected to show steady growth over the forecast period, due to various factors, including the continued efforts of New Zealand’s Ministry of Health, along with various other entities with a similar focus. Obesity rates in New Zealand are expected to show a slight to moderate decline over the forecast period, with the health and wellness trend being a contributing factor. Increased education regarding the importance of a healthy diet and regular exercise, along with the risks associated with obesity, is expected. The category is expected to show a forecast period CAGR of 1%, reaching retail sales of NZ$42 million in 2015.

CATEGORY DATA

  • Table 113 Sales of Weight Management: Value 2005-2010
  • Table 114 Sales of Weight Management: % Value Growth 2005-2010
  • Table 115 Weight Management Company Shares 2006-2010
  • Table 116 Weight Management Brand Shares 2007-2010
  • Table 117 Forecast Sales of Weight Management: Value 2010-2015
  • Table 118 Forecast Sales of Weight Management: % Value Growth 2010-2015

Wound Care in New Zealand - Category Analysis

HEADLINES

TRENDS

  • The wound care category is mature, and this was reflected in 2010’s growth rate of 2% being marginally lower than the review period CAGR of approaching 4%. The category lacked new innovations and new product launches in 2010.

COMPETITIVE LANDSCAPE

  • The Band-Aid brand by Johnson & Johnson Pacific (NZ) Ltd remained the leader within sticking plasters/adhesive bandages in 2010, with a retail value share of 21%. The brand’s dominance is due to high awareness and the brand’s perceived high quality.

PROSPECTS

  • Over the forecast period wound care in New Zealand is expected to see a 1% constant value CAGR, achieving sales worth NZ$11 million in 2015.

CATEGORY DATA

  • Table 119 Sales of Wound Care by Category: Value 2005-2010
  • Table 120 Sales of Wound Care by Category: % Value Growth 2005-2010
  • Table 121 Wound Care Company Shares by Value 2006-2010
  • Table 122 Wound Care Brand Shares by Value 2007-2010
  • Table 123 Forecast Sales of Wound Care by Category: Value 2010-2015
  • Table 124 Forecast Sales of Wound Care by Category: % Value Growth 2010-2015

Segmentation

Segmentation

This market research report includes the following:

  • Consumer Health
    • OTC
      • Adult Mouth Care
      • Analgesics
        • Systemic Analgesics
          • Adult Analgesics
            • Acetaminophen
            • Aspirin
            • Combination Products - Analgesics
            • Diclofenac
            • Dipyrone
            • Ibuprofen
            • Ketoprofen
            • Naproxen
          • Child-Specific Analgesics
            • Child-Specific Acetaminophen
            • Child-Specific Aspirin
            • Child-Specific Combination Products - Analgesics
            • Child-Specific Diclofenac
            • Child-Specific Dipyrone
            • Child-Specific Ibuprofen
            • Child-Specific Ketoprofen
            • Child-Specific Naproxen
        • Topical Analgesics/Anaesthetic
      • Calming and Sleeping
      • Cough, Cold and Allergy (Hay Fever) Remedies
        • Antihistamines/Allergy Remedies (Systemic)
        • Child-Specific Cough, Cold and Allergy Remedies
          • Child-Specific Allergy Remedies
          • Child-Specific Cough/Cold Remedies
        • Combination Products - Cough, Cold and Allergy (Hay Fever) Remedies
        • Cough Remedies
        • Decongestants
          • Nasal Sprays
          • Oral Decongestants
          • Inhalant Decongestants
          • Decongestant Rubs
          • Nasal Decongestant Drops
          • Nasal Decongestant Plasters
        • Medicated Confectionery
        • Pharyngeal Preparations
      • Digestive Remedies
        • Child-Specific Digestive Remedies
          • Child-Specific Diarrhoeal Remedies
          • Child-Specific Indigestion and Heartburn Remedies
          • Child-Specific Laxatives
          • Child-Specific Motion Sickness Remedies
        • Diarrhoeal Remedies
        • IBS Treatments
        • Indigestion and Heartburn Remedies
          • Antacids
          • Antiflatulents
          • Digestive Enzymes
          • H2 Blockers
          • Proton Pump Inhibitors
        • Laxatives
        • Motion Sickness Remedies
      • Ear Care
      • Emergency Contraception
      • Eye Care
        • Allergy Eye Care
        • Standard Eye Care
      • Medicated Skin Care
        • Acne Treatments
        • Medicated Shampoos
        • Topical Antifungals
        • Vaginal Antifungals
        • Hair Loss Treatments
        • Nappy (Diaper) Rash Treatments
        • Antiparasitics/Lice (Head and Body) Treatments
        • Antipruritics
        • Child-Specific Medicated Skin Care
        • Cold Sore Treatments
        • Haemorrhoid Treatments
        • Topical Allergy Remedies/Antihistamines
        • Topical Germicidals/Antiseptics
      • NRT Smoking Cessation Aids
        • NRT Gum
        • NRT Inhalators
        • NRT Lozenges
        • NRT Patches
        • Other NRT
      • OTC Triptans
      • Wound Care
        • First Aid Kits
        • Sticking Plasters/Adhesive Bandages
        • Gauze, Tape and Other Wound Care
    • Sports Nutrition
    • Vitamins and Dietary Supplements
      • Child-Specific Vitamins and Dietary Supplements
      • Dietary Supplements
        • Combination Dietary Supplements
        • Herbal/Traditional Dietary Supplements
          • Combination Herbal/Traditional Dietary Supplements
          • Echinacea
          • Evening Primrose Oil
          • Garlic
          • Ginkgo Biloba
          • Ginseng
          • St John's Wort
          • Other Herbal/Traditional Dietary Supplements
            • Green Tea Extract
            • Isoflavones
            • Microalgae
            • Other Other Herbal/Traditional Dietary Supplements
        • Non-Herbal Dietary Supplements
          • Calcium Supplements
          • Co-Enzyme Q10
          • Combination Non-Herbal Dietary Supplements
          • Eye Health Supplements
          • Fish Oils
            • Cod Liver Oil
            • Other Fish Oils
          • Glucosamine
          • Mineral Supplements
          • Omega-3-6-9 (Fish and Non-Fish)
          • Probiotic Supplements
          • Protein Powder
          • Royal Jelly
          • Sam-E
          • Other Non-Herbal Dietary Supplements
        • Tonics and Bottled Nutritive Drinks
        • Vitamins
          • Multivitamins
          • Single Vitamins
            • Vitamin A
            • Vitamin B
            • Vitamin C
            • Vitamin D
            • Vitamin E
            • Other Single Vitamins
      • Weight Management
        • Meal Replacement Slimming
        • OTC Obesity
        • Slimming Teas
        • Weight Loss Supplements
        • Other Slimming Products
      • Herbal/Traditional Products
        • Herbal/Traditional Analgesics
        • Herbal/Traditional Calming and Sleeping Products
        • Herbal/Traditional Cough, Cold and Allergy (Hay Fever) Remedies
        • Herbal/Traditional Digestive Remedies
        • Herbal/Traditional Medicated Skin Care
        • Herbal/Traditional Medicinal Teas
        • Herbal/Traditional Smoking Cessation Aids
        • Herbal/Traditional Child-Specific Dietary Supplements
        • Herbal/Traditional Dietary Supplements
        • Herbal/Traditional Tonics and Bottled Nutritive Drinks
      • Allergy Care
        • Allergy Eye Care
        • Antihistamines/Allergy Remedies (Systemic)
        • Child-Specific Allergy Remedies
        • Topical Allergy Remedies/Antihistamines
      • Child-Specific Consumer Health
        • Child-Specific Analgesics
          • Child-Specific Acetaminophen
          • Child-Specific Aspirin
          • Child-Specific Combination Products - Analgesics
          • Child-Specific Diclofenac
          • Child-Specific Dipyrone
          • Child-Specific Ibuprofen
          • Child-Specific Ketoprofen
          • Child-Specific Naproxen
        • Child-Specific Cough, Cold and Allergy Remedies
          • Child-Specific Allergy Remedies
          • Child-Specific Cough/Cold Remedies
        • Child-Specific Digestive Remedies
          • Child-Specific Diarrhoeal Remedies
          • Child-Specific Indigestion and Heartburn Remedies
          • Child-Specific Laxatives
          • Child-Specific Motion Sickness Remedies
        • Child-Specific Medicated Skin Care
        • Nappy (Diaper) Rash Treatments
        • Child-Specific Vitamins and Dietary Supplements

    Statistics Included

    Statistics Included

    For each category and subcategory you will receive the following data in Excel format:

    From Passport

    • Market sizes
    • Company shares
    • Brand shares
    • Distribution
    • Analysis by format
    • Analysis by positioning
    • Analysis by type
    • Herbal/traditional vs standard
    • Pricing
    • Smoking incidence

    Market size details:

    • Retail volume
    • Retail volume % growth
    • Retail volume per capita
    • Retail value retail selling price % growth
    • Retail value retail selling price local currency, USD, EUR, GBP, CHF, JPY
    • Retail value retail selling price per capita local currency, USD, EUR, GBP, CHF, JPY
    • Retail value retail selling price real (constant 2008) prices % growth
    • Retail value retail selling price real (constant 2008) prices local currency, USD, EUR, GBP, CHF, JPY
    • Retail value retail selling price real (constant 2008) prices per capita local currency, USD, EUR, GBP, CHF, JPY
    • Retail value manufacturer selling price % growth
    • Retail value manufacturer selling price local currency, USD, EUR, GBP, CHF, JPY
    • Retail value manufacturer selling price per capita local currency, USD, EUR, GBP, CHF, JPY
    • Retail value manufacturer selling price real (constant 2008) prices % growth
    • Retail value manufacturer selling price real (constant 2008) prices local currency, USD, EUR, GBP, CHF, JPY
    • Retail value manufacturer selling price real (constant 2008) prices per capita local currency, USD, EUR, GBP, CHF, JPY
    • Retail value retail selling price nominal (current) prices % growth
    • Retail value retail selling price nominal (current) prices local currency, USD, EUR, GBP, CHF, JPY
    • Retail value retail selling price nominal (current) prices per capita local currency, USD, EUR, GBP, CHF, JPY
    • Retail value manufacturer selling price nominal (current) prices % growth
    • Retail value manufacturer selling price nominal (current) prices local currency, USD, EUR, GBP, CHF, JPY
    • Retail value manufacturer selling price nominal (current) prices per capita local currency, USD, EUR, GBP, CHF, JPY

    Methodology

    Methodology

    Global insight and local knowledge

    With 40 years’ experience of developed and emerging markets, Euromonitor International’s research method is built on a unique combination of specialist industry knowledge and in-country research expertise.

    This approach is what enables us to achieve our goal of building a market consensus view of size, shape and trends across the full distribution universe of each category. We factor in whichever channels are relevant, from large-scale grocery to direct sellers, from discount stores to local mom-and-pop outlets.

    Industry specialists

    Each industry we cover is managed by an Industry Manager and team of Industry Analysts who research and report on their specialist categories all year round.

    Our collaborative approach to research means that these industry teams are in constant dialogue with industry players and opinion formers. The planning of our research programmes reflects latest market trends and industry events. In completing each update project, this provides invaluable input to the testing, review and finalisation of our data.

    The specialist in-house teams bring together findings from all stages of the annual research process. They work closely with in-country analysts, assess and challenge data and exercise final editorial control over the publication of new data and analysis.

    Country and regional analysts

    Our in-country analyst network is managed by country and regional analysts in our offices around the world. Working closely with each in-country team, the regional research management team ensures that all country researchers are well schooled in best practices, from the information collected in store checks, to the dialogue we build in trade surveys. Our country analysts ensure that national reports explain the data trends and provide clear insights into the local market’s dynamics.

    In-country research network

    To deliver fresh insights every year in countries all around the world, we believe the strongest approach is to use analysts on the ground. They bring fluency in local language, physical proximity to the best sources, an ability to engage directly with local industry contacts, and an awareness of how the products and services we study are advertised, sold and consumed. These are essential parts of our ability to report incisively on these markets.

    Research Methodology

    Our research methods

    Each Euromonitor International industry report is based on a core set of research techniques:

    Desk research

    With industry events, corporate activity, trends and new product introductions tracked year round by our industry team, desk research provides a starting point for the in-country research programme. Our in-country researchers will access the following sources:

    • National statistics offices governmental and official sources
    • National and international trade press
    • National and international trade associations
    • Industry study groups and other semi-official sources
    • Company financials and annual reports
    • Broker reports
    • Online databases
    • The financial, business and mainstream press

    Accessing sources is only the first step. The ability to interpret and reconcile often conflicting information across multiple sources is a key aspect of the added value we provide.

    Store checks

    Store checks are an integral part of our methods for product industries. Carried out on the ground across a relevant mix of channels, the information gained provides first-hand insights into the products we are researching, specifically:

    • Place: We track products in all relevant channels, selective and mass, store and non-store
    • Product: What are innovations in products, pack sizes and formats?
    • Price: What are brand price variations across channels, how do private label’s prices compare to those of branded goods?
    • Promotion: What are marketing and merchandising trends, offers, discounts and tie-ins?

    Findings are cross-referenced with brand share data analysis. The results, combined with the findings of desk research, provide a strong basis for identifying key areas of questioning to take forward into our trade survey.

    Trade survey

    Interaction with global players at corporate HQ and regional levels is complemented by unique local data and insights from our in-country trade surveys around the world. Through the high profile of the Euromonitor International brand, we are able to talk directly to a wide range of sources and therefore inform our analysis with the knowledge and opinions of the leading operators in the market.

    Trade surveys allow us to:

    • Fill gaps in available published data per company
    • Generate a consensus view of the size, structure and strategic direction of the category
    • Access year-in-progress data where published sources are out of date
    • Evaluate the experts’ views on current trends and market developments

    In building our composite industry view, we engage with a variety of personnel in key players at all points of the supply chain: materials suppliers, manufacturers, distributors, retailers and service operators. We also interview desk research sources: industry associations; study groups; and third party observers from the trade and financial press.

    Our objective is to engage in conversation with trade sources in which we exchange ideas and views on the industry, sharing our work-in-progress findings on supply/demand dynamics and potential. This dialogue enhances both parties’ understanding of the local market. The scope and reach of our trade survey also serves to eliminate bias (intentional and unintentional) from any single source.

    Company analysis

    At a global level, our company research combines our mix of industry interaction and use of secondary sources such as annual accounts, broker reports, financial press and databases. From a data perspective, the aim is to build “top-down” estimates of major players’ total global and regional sales.

    At a country level, in line with local reporting requirements, we access annual accounts, national-specific company databases and local company websites. These are all invaluable sources as we build a view of each domestic player’s size and position within very specific categories of the industry.

    Forecasts

    Data projections and future performance analysis are key elements of Euromonitor International’s market intelligence. Working with historic trends of 15 years or more, a key aspect of our trade survey is to engage industry insider views of the next five years. Will volumes maintain their historic trend? Will price increases or falls of recent years continue, accelerate or slow down? Will increasing demand for one product cannibalise sales of another?

    Forecasts represent many of the essential conclusions we have reached about the current state of the market, how it works and how it behaves under different macro and micro conditions. Our written analysis will state the assumptions and the trade opinion behind whether our predictions are optimistic or pessimistic, so that clients can use our statistical forecasts with confidence.

    Data validation

    All data is subjected to an exhaustive review process, at country, regional and global levels.

    The interpretation and review of sources and data inputs forms a central part of the collaboration between industry teams and country researchers. Numbers are delivered to regional and global offices with an audit trail of sources and calculations to allow for a thorough evaluation of data sense and integrity.

    Upon completion of the country review phase, data is then reviewed on a comparative basis at regional and then at a global level. Comparative checks are carried out on per capita consumption and spending levels, growth rates, patterns of category and subcategory breakdowns and distribution of sales by channel. Top-down estimates are reviewed against bottom-up regional and global market and company sales totals.

    Where marked differences are seen between proximate country markets or ones at similar developmental levels, supplementary research is conducted in the relevant countries to confirm and/or amend those findings. This process ensures international comparability across the database, that consistent category and subcategory definitions have been used and that all data has been correctly tested. We make sure that possible discrepancies between different published sources have been reconciled and that our interpretation of opinion and expectation from each country’s trade sources has been applied to form a coherent international pattern.

    Market analysis

    Another integral part of all our research programmes is that all Euromonitor International data is accompanied by clear written analysis. From a research perspective, this explains and substantiates data findings. From a client perspective, this offers unique insights into local consumption trends, routes to market, brand preferences, channel dynamics and future trends.

    Our country level analysis also provides invaluable input into the ability of our central industry specialist teams to marry local insights with strategic conclusions on the direction of the market regionally and globally.

    my pages

    Want to find out more about this report?

    RELATED

    Country Report

    Consumer Lifestyle

    Future Demographic

    Country Report